MedTrace Logo

Abemaciclib With or Without Atezolizumab for mCRPC

NCT04751929 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-02-20

Study results available
· View outcomes & findings →

Summary

This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing the safety of the combination of abemaciclib with atezolizumab.

Conditions

Interventions

DRUG

Abemaciclib

Taken orally 2x daily

DRUG

Atezolizumab

Intravenously Day 1 of 21 day cycle

Sponsors & Collaborators

Principal Investigators

  • Atish Choudhury, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-20
Primary Completion
2024-06-17
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04751929 on ClinicalTrials.gov